Amneal Pharmaceuticals (AMRX) Scheduled to Post Quarterly Earnings on Friday

Amneal Pharmaceuticals (NASDAQ:AMRX) is scheduled to be releasing its earnings data before the market opens on Friday, November 8th. Analysts expect Amneal Pharmaceuticals to post earnings of $0.11 per share for the quarter. Amneal Pharmaceuticals has set its FY 2024 guidance at 0.570-0.630 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.04. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. The company had revenue of $701.78 million during the quarter, compared to analyst estimates of $657.43 million. On average, analysts expect Amneal Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amneal Pharmaceuticals Trading Down 1.2 %

Amneal Pharmaceuticals stock opened at $8.47 on Friday. The business’s 50 day simple moving average is $8.53 and its 200 day simple moving average is $7.41. Amneal Pharmaceuticals has a 12 month low of $3.72 and a 12 month high of $8.95. The company has a market cap of $2.61 billion, a price-to-earnings ratio of -15.13 and a beta of 1.18.

Analyst Ratings Changes

AMRX has been the subject of several research reports. Barclays increased their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. Finally, Truist Financial increased their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.